Ottimo Pharma

Ottimo Pharma is a privately-held biotechnology company co-founded by Medicxi and Jonny Finlay in 2020, focusing on developing groundbreaking innovative cancer therapies for solid tumors. The company’s lead program, Jankistomig, is a PD1-VEGFR2 bifunctional antibody designed to simultaneously target immune checkpoint inhibition and angiogenesis through a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce the overall healthcare burden.